Eversept Partners LP Has $155.58 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Eversept Partners LP lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 9.4% in the fourth quarter, HoldingsChannel reports. The fund owned 3,072,304 shares of the company’s stock after acquiring an additional 264,468 shares during the period. Vera Therapeutics makes up approximately 7.8% of Eversept Partners LP’s holdings, making the stock its largest holding. Eversept Partners LP’s holdings in Vera Therapeutics were worth $155,581,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Vera Therapeutics by 7.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after acquiring an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after purchasing an additional 17,907 shares during the period. Jane Street Group LLC boosted its stake in Vera Therapeutics by 297.1% in the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. boosted its stake in Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares during the period. Finally, Legal & General Group Plc boosted its stake in Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after purchasing an additional 825 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on VERA. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Finally, HC Wainwright upped their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at $7,963,174.56. This represents a 7.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Vera Therapeutics Stock Up 4.0%

Shares of VERA opened at $35.01 on Thursday. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.32 and a beta of 0.93. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The business’s 50 day simple moving average is $36.63 and its 200-day simple moving average is $41.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm earned ($0.81) earnings per share. As a group, equities analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.